Replies to post #16696 on Mymetics Corp (MYMX)

[bow-tie]

HER2-Vaxx (developed by Imugene)
induces polyclonal antibody responses against a speci?c epitope
of HER2 and is being tested in patients with HER2-positive
gastric, esophageal, and breast cancers. In the current vaccine, the
HER2 peptide is formulated using the carrier protein CRM197,
a non-toxic mutant of diphtheria toxin, combined with an
adjuvant, whereas the previous formulation used virosome-based
materials.

Mymetics to manufacture HER-Vaxx cancer immunotherapy
22-Jul-2014 By Zachary Brennan
Swiss-based Mymetics has agreed with Australian biotech Imugene to manufacture and develop its cancer immunotherapy HER-Vaxx, which is expected to enter into a Phase I/II clinical trial in 2015.
https://www.biopharma-reporter.com/Article/2014/07/22/Mymetics-to-manufacture-HER-Vaxx-cancer-immunotherapy